162 related articles for article (PubMed ID: 37748181)
1. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
Bajaj HS; Aberle J; Davies M; Donatsky AM; Frederiksen M; Yavuz DG; Gowda A; Lingvay I; Bode B
Ann Intern Med; 2023 Nov; 176(11):1476-1485. PubMed ID: 37748181
[TBL] [Abstract][Full Text] [Related]
2. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
[TBL] [Abstract][Full Text] [Related]
3. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
[TBL] [Abstract][Full Text] [Related]
4. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
[TBL] [Abstract][Full Text] [Related]
5. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
Shetty S; Suvarna R
Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC
Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084
[TBL] [Abstract][Full Text] [Related]
10. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
[TBL] [Abstract][Full Text] [Related]
12. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
[TBL] [Abstract][Full Text] [Related]
13. Once-Weekly Insulin Icodec
Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis.
Mukhopadhyay P; Chatterjee P; Pandit K; Sanyal D; Ghosh S
Endocr Pract; 2024 Feb; 30(2):128-134. PubMed ID: 37984730
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Sep; 16(9):102615. PubMed ID: 36108418
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Hövelmann U; Engberg S; Heise T; Kristensen NR; Nørgreen L; Zijlstra E; Ribel-Madsen R
Diabetes Obes Metab; 2024 May; 26(5):1941-1949. PubMed ID: 38379002
[TBL] [Abstract][Full Text] [Related]
17. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
[TBL] [Abstract][Full Text] [Related]
18. In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA
Liakos A; Karagiannis T; Tsapas A
Ann Intern Med; 2024 Jan; 177(1):JC6. PubMed ID: 38163368
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
